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Abstract
Objective. Previous studies have documented
memory impairment in several chronic pain syndromes. However, the potential link between memory loss and osteoarthritis (OA), the second most
common cause of chronic pain, remains little explored. In this cross-sectional study, we examine
the association of perceived memory loss to OA
and assess the potential mediating influence of
sleep and mood disturbance in a large Appalachian
population.

Subjects. A total of 21,982 Appalachian adults age
40 years or older drawn from the C8 Health Project
(N 5 19,004 adults without and 2,478 adults with
OA). All participants completed a comprehensive
health survey between 2005 and 2006. Medical history, including physician diagnosis of OA, lifestyle
factors, short- and long-term memory loss, sleep
quality, and mood were assessed via self-report.
Results. After adjustment for demographic, lifestyle, health-related, and other factors, participants
with OA were almost three times as likely to report
frequent memory loss (adjusted odds ratios [ORs]
for short- and long-term memory loss, respectively 5 2.7, 95% confidence interval [CI] 5 2.2–3.3,
and 2.6, 95% CI 5 2.0–3.3). The magnitude of these
associations increased significantly with rising frequency of reported joint pain (adjusted OR for OA
with frequent joint pain vs no OA 5 3.3, 95%
CI 5 2.6–4.1, Ptrend < 0.00001). Including measures of
mood and sleep impairment attenuated but did not
eliminate these associations (ORs for any memory
loss 5 2.0, 95% CI 5 1.6–2.4, and 2.1, 95% CI 5 1.7–
2.8, adjusted for sleep and mood impairment, respectively; OR 5 1.8, 95% CI 5 1.4–2.2, adjusted for
both factors).
Conclusions. In this large cross-sectional study, OA
and related joint pain were strongly associated with
perceived memory loss; these associations may be
partially mediated by sleep and mood disturbance.
Key Words. Cognition; Memory Loss; Osteoarthritis;
Chronic Pain; Mood; Sleep
Introduction
Chronic pain, defined as pain lasting more than
12 weeks [1], is a common and costly condition. A 2016
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meta-analysis of 19 population-based prevalence studies (N ¼ 139,933 adults) estimated that between onethird and one-half of the UK adult population is affected
by chronic pain (pooled estimate of 43.5%) [2]. In an
age-standardized analysis of general population surveys
of 42,248 adults from 18 countries, 37% of respondents
in developed countries and 41% in developing countries
reported a chronic pain condition [3]; of the 10 developed
countries included in the study, the highest prevalence
was reported in the United States (44%) and France
(50%). Moreover, for many with chronic pain, symptoms
are severe and relentless. In Europe, an estimated 19%
of the adult population suffers moderate to severe
chronic pain, a large proportion of which has inadequate
pain control [4–6]. In a study of a nationally representative
sample of more than 27,000 US adults, 31% reported
experiencing chronic pain, of whom 50% indicated daily
pain and 32% indicated severe pain [7]. Furthermore, as
most studies exclude or underrepresent frail elderly and
individuals in long-term care, these figures may reflect underestimates of true prevalence [6].
Chronic pain is associated with high direct and indirect
health care costs and with substantial individual and societal burden. In the United States, excess health care
costs attributable to persistent pain in adults are estimated to total $261 to $300 billion in 2010 dollars [8].
Chronic pain can lead to significant declines in productivity, physical function, quality of life, and overall health,
mood, and well-being [2,3,6,9,10] and is a leading
cause of disability both in the United States and globally
[11,12]. In addition, chronic pain can have profound effects on neurocognitive function. Because the neural
systems involved in memory and cognition are closely
linked to those involved in pain processing, these systems may affect one another reciprocally [9,13], disrupting cognitive processing and contributing to a
vicious cycle of continuing pain, adverse neurostructural changes, and deteriorating cognitive function.
Patients with chronic pain do, in fact, show changes
in brain morphology paralleling those impairment;
these changes include gray matter reduction in the insular cortex, anterior cingulate cortex, thalamus, prefrontal cortex [9,13–16], and other brain regions
involved not only in pain processing and emotional regulation, but in attention, memory consolidation, and cognitive processing. In addition, chronic pain has been
shown to disrupt the functioning of the default mode network [16] and other brain networks [16] essential to normal cognitive function. These alterations are thought to
help explain the reductions in memory and cognitive performance documented in a number of populations with
chronic pain [9].
Memory impairment has been reported in several
chronic pain syndromes, including migraine headaches,
chronic low back pain, diabetic neuropathy, rheumatoid
arthritis, and fibromyalgia [9,17]. However, the link between memory loss and osteoarthritis (OA), the most
common form of arthritis, a major contributor to disability [11] and the second most common cause of chronic

pain [7], remains little explored. In this cross-sectional
study, we examine the association of perceived memory
loss to osteoarthritis and frequency of associated joint
pain in a large population of Appalachian adults.
Methods
Study Population and Data Source
The sample for this study was drawn from the C8
Health Project [18,19], which arose from the settlement
of a class action lawsuit associated with perfluorooctane
(PFOA) contamination of drinking water by a chemical
plant in Washington, West Virginia. Baseline data on
69,030 individuals living or working in six PFOA-contaminated water districts in Ohio and West Virginia were
collected from August 2005 to August 2006. As part of
the C8 Health Project, participants completed a comprehensive health survey administered by trained personnel; blood samples were also collected to assess
clinical biomarkers and serum levels of PFOA and other
perfluorocarbons [19]. Project data collection was administered by Brookmar, Inc. (Parkersburg, WV, USA)
and conducted under the authority and supervision of
the Wood County, West Virginia, Circuit Court [19,20].
Participants were informed that central objectives of the
Health Project were to determine levels of PFOA in the
blood and to explore any potential associations between
PFOA serum levels and diseases. Project details, from
consent and enrollment to data collection, cleaning, and
reporting, have been published elsewhere [19]. Blood
processing and analytical methods, as well as qualityassurance measures, have also been previously
described in detail [18,19,21]. Informed consent was obtained using a process approved by parties to the settlement and language specific to the project’s objectives
and data collection procedures [19,20]. This study was
based on aggregate, deidentified data and approved by
the West Virginia University Institutional Review Board.
The estimated participation rate in the C8 Health Project
among adult residents of the affected water districts
was 81% [18]. For the current study, eligible participants
included all adults age 40 years or older at the time of
baseline assessment (N ¼ 33,386 individuals). As illustrated in Figure 1, those who reported a physician diagnosis of rheumatoid arthritis, fibromyalgia, or another
chronic pain syndrome other than OA (N ¼ 7,128) were
excluded from the analyses; also excluded were those
diagnosed with conditions linked to impaired cognitive
function (either the conditions themselves or their treatment),
including
stroke,
Alzheimer’s
disease,
Parkinson’s disease, multiple sclerosis, and cancer
(other than nonmelanoma skin cancer, N ¼ 3,782), leaving a total of 22,926 eligible adults. Exclusion of those
with missing data on memory loss, OA joint pain severity, and/or other covariates of interest (N ¼ 842, 3.67%)
yielded a final study sample of 21,982, including 19,004
without and 2,478 adults with OA (see Figure 1).
Relative to participants included in the analyses, those
with missing data on any covariate were more likely to
1341
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33,386 adults 40+ years of age enrolled in C8
health project
Exclude parcipants reporng a physician
diagnosis of rheumatoid arthris, ﬁbromyalgia,
and other chronic pain syndromes (N = 7,128)
Remaining eligible parcipants: 26,374 adults
Exclude parcipants with history of stroke,
Alzheimer’s disease, Parkinson’s disease,
mulple sclerosis, or cancer (N = 3,782)
Remaining eligible parcipants: 22,926 adults
Exclude parcipants with missing data on
OA, memory loss, or any covariate of interest
(N = 842, 3.67%)
Final study sample for analysis: 21,982 adults
(2,478 adults with OA)

Figure 1 Study flow diagram. OA ¼ osteoarthritis.
be female, older, and less educated and to indicate
lower family income and a history of alcohol consumption; Participants with missing data were also less likely
to be employed outside the home or to report having a
regular exercise program or ever smoking (P < 0.01).
There were no differences in other demographic and
lifestyle characteristics, prevalence of OA, obesity, or
other chronic conditions, medication use, reported
memory loss, or other factors.
Outcome and Exposure Measurements
Primary Outcome
Recent and long-term memory loss was ascertained via
responses to two Likert scale questions: 1) “Have you experienced short-term memory loss?” and 2) “Have you experienced long-term memory loss?” Response choices
were “never,” “rarely,” “sometimes,” and “frequently.”
Short-term memory loss was scored as present (1) if the
response was “frequently” to question 1; long-term memory loss was considered present if the participant responded “frequently” to question 2. All other responses
were coded as 0. Any perceived memory loss, the primary
outcome variable, was scored as positive if either shortor long-term memory loss was coded as present (1).

Key Exposure Variables
Physician diagnosis of osteoarthritis was assessed via
self-report questionnaires. While self-reported diagnosis
of osteoarthritis was not externally verified, a previous
validation study demonstrated more than 80%
1342

agreement between self-reported and clinically confirmed diagnosis of OA [22], comparable with the 74%
concordance observed between self-report and medical
record–verified data on another common chronic disorder (diabetes) in the C8 Health Study population [23].
OA symptom frequency was evaluated using responses
to a single Likert scale question regarding the participant’s experience of joint pain (“never,” “rarely,” “sometimes,” and “frequently”).

Other Explanatory Variables
Demographics (age, sex, education, race/ethnicity, marital status, income, employment), lifestyle factors (physical activity, alcohol consumption, smoking), medication
use, and health characteristics (medical and reproductive history, weight, height) were also determined via
self-report; demographic data and health survey completion were verified by trained project staff. Reported
physician diagnoses of certain disorders, including cancer, diabetes, and cardiovascular disease, were further
verified via chart review. Sleep quality and mood disturbance were assessed via a series of Likert scale questions. A composite sleep quality variable, with higher
scores indicating poorer sleep quality, was derived from
responses to four items regarding the frequency of short
sleep, fitful sleep, insomnia, and daytime somnolence
(with each item scored as follows: 3 ¼ “frequently,” 2 ¼
“sometimes,” 1 ¼ “rarely,” 0 ¼ “never”). Mood disturbance was also assessed as a composite variable derived from responses to three questions regarding mood
swings, irritability, and inability to concentrate; items
were scored using a similar scoring system (3 ¼ “frequently,” 2 ¼ “sometimes,” 1 ¼ “rarely,” 0 ¼ “never”).

Osteoarthritis and Reported Memory Loss
Statistical Analysis

Results

Data were analyzed using IBM SPSS Statistics version
23. We used logistic regression analysis to evaluate the
associations of OA to reported frequency of memory
loss (short-term memory loss, long-term memory loss,
and any memory loss); to assess the influence of potential confounders, and to evaluate potential mediators
and effect modifiers. Linear trends were assessed using
polynomial contrasts. Potential differences between participants with and without missing data were evaluated
using the Student’s t test or Mann-Whitney U test for
continuous or ordinal variables and the chi-square test
for categorical variables. The primary explanatory variable of interest, OA, was analyzed as both a dichotomous variable (yes/no) and by reported frequency of
joint pain (OA with joint pain never/rarely, sometimes,
and frequently), with no OA used as the referent category. All P values presented are two-sided.

Table 1 illustrates the distribution of study population
characteristics by presence of perceived memory loss.
Participants were predominantly non-Hispanic white
(97%), ranging in age from 40 to 97 years (mean ¼
54.21 years, SD ¼ 10.77 years). Fifty-one percent were
female, 56% had received only 12 years of schooling or
less, and 30% reported a mean annual household income of less than $30,000. Sixty-one percent were employed, and approximately 6% were disabled. More
than 50% reported smoking currently (22%) or previously (29%), and only 33% indicated engagement in a
regular exercise program. More than 30% of the adults
in this population were obese (BMI  30), with a mean
BMI of 28.87 (5.93).

Factors on which adequate data were available and
which have been previously linked to either OA and/or
memory loss were selected a priori as covariates.
Associations of OA to memory were initially adjusted for
age and gender, factors strongly related to both pain
and OA. Unless stated otherwise, all other multivariable
models were adjusted for the following: age, gender,
race/ethnicity, marital status, socioeconomic status
([SES] including years of education, average family
income, and employment status/disability); lifestyle factors (participation in a regular exercise program [yes/no],
smoking [never, former, current], history of alcohol consumption [yes/no]) menopausal status; and use of hormone replacement therapy (women), body mass index
(BMI); medical comorbidity (reported physician diagnosis
of other medical conditions, including heart, kidney,
liver, thyroid, immune, and connective tissue disease,
stroke, hypertension, dyslipidemia, diabetes, chronic obstructive pulmonary disease, or asthma); current treatment for hypertension or hyperlipidemia, hormone
replacement therapy, and other prescription medications. While the latter category includes analgesic medications, information available in the data set did not
allow adjustment for nonsteroidal anti-inflammatory
(NSAID) or other individual analgesics. Additional analyses adjusted for serum levels of PFOA (mg/L) and for
military service and associated exposures to harmful
chemicals.
To evaluate the potential modifying effects of gender,
age, and obesity on the association of perceived memory loss to history of OA, we conducted multivariable
analyses stratified by each potential effect modifier. We
tested the strength of each interaction by including the
corresponding multiplicative interaction term in the main
adjusted statistical model and evaluating the coefficient
using the Wald test. We also assessed potential mediating influences of sleep impairment and mood disturbance, defined as detailed above.

Of the 21,982 eligible participants, 719 (3.3%) indicated
experiencing frequent short- or long-term memory loss.
After adjustment for other factors in the table, women
remained significantly more likely to report frequent
memory loss than men (61 vs 39%, respectively, adjusted P ¼ 0.001), as did those who were divorced or
separated relative to those who were married or
cohabiting (OR ¼ 1.5, 95% CI ¼ 1.2–1.8, adjusted
P ¼ 0.002). Perceived memory loss also retained significant positive associations with alcohol consumption,
current and former tobacco smoking, obesity, and history of hormone replacement therapy, and significant
negative associations with educational level, household
income, and engagement in a regular exercise program
(Table 1). Participants who were retired, homemakers or
unemployed, who were disabled, who had been diagnosed with at least one chronic medical condition other
than OA, or who were taking prescription medications
other than lipid-lowering and antihypertensive drugs
were also significantly more likely to report memory loss
(adjusted P <0.0001).
Table 2 illustrates the associations of perceived memory loss with reported history of OA and OA symptom
frequency. A total of 2,478 participants (11.3%) reported a physician diagnosis of OA, of whom 62%
(N ¼ 1532) indicated frequent joint pain. OA showed a
strong, significant, positive relation to perceived memory loss in both the minimally adjusted analysis and
the full models. Those reporting a diagnosis of OA
were approximately four times as likely to report memory loss than those without OA (odds ratio [OR] ¼ 3.9,
95% confidence interval [CI] ¼ 3.2–4.6, P < 0.00001)
after adjustment for age and sex. Further adjustment
for race, education, marital status, income employment, and lifestyle factors slightly diminished this association (OR ¼ 3.1, 95% CI ¼ 2.6–3.8). OA remained
strongly and positively related to perceived memory
loss after additional adjustment for BMI, comorbidity,
medication use, menopausal status, and use of hormone replacement therapy (OR ¼ 2.6, 95% CI ¼ 2.2–
3.2).
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Table 1 Characteristics of adults  40 years of age from 6 Ohio Valley water districts, stratified by
reported history of frequent memory loss
Frequent Memory Loss

Demographics
Age, y
Per year increment
Age, mean (SD), y
Gender
Male
Female
Ethnicity
White
Minority
Marital status
Married/cohabiting
Single
Divorced/separated
Widowed
Years of education
<12
High school/GED
Some college
4þ y college
Current employment status
Employed
Homemaker
Retired
Unemployed/laid off
Student
Disabled
Other
Average household income
<$30,000
$30,000–$70,000
>$70,000
Don’t know/missing
Lifestyle factors
Alcohol consumption ever
No
Yes
Smoking status
Never
Former
Current
Regular exercise program
No
Yes
Anthropometrics and medical history
BMI, kg/m2
<30
30þ
BM, mean (SD)

No (N ¼ 19,004)

Yes (N ¼ 719)

N

N

%

%

Adjusted OR* (95% CI) P†

1.00 (0.99–1.01)
54.20 (10.76)

54.24 (11.20)

11,027
10,236

51.86
48.14

278
441

38.66
61.34

1.00 (referent)
1.47 (1.16–1.87)

20,689
574

97.30
2.70

699
20

97.22
2.78

1.00 (referent)
0.99 (0.63–1.57)

16,765
1,069
2,331
1,098

78.85
5.03
10.96
5.16

496
36
140
47

68.98
5.01
19.47
6.54

1.00
0.90
1.48
1.09

(referent)
(0.63–1.28)
(1.21–1.82)
(0.78–1.53)

2,237
9,589
6,429
3,008

10.52
45.10
30.24
14.15

123
283
244
69

17.11
39.36
33.94
9.60

1.00
0.78
1.01
0.80

(referent)
(0.62–0.99)
(0.79–1.30)
(0.57–1.13)

13,041
2,397
4,036
586
68
1,001
134

61.33
11.27
18.98
2.76
0.32
4.71
0.63

321
84
119
27
6
150
12

44.65
11.68
16.55
3.76
0.83
20.86
1.67

1.00
1.21
1.38
1.81
2.86
4.46
2.96

(referent)
(0.93–1.59)
(1.05–1.82)
(1.20–2.72)
(1.22–6.74)
(3.51–5.67)
(1.60–5.46)

6,371
9,208
3,897
1,787

29.96
43.31
18.33
8.40

306
278
78
57

42.56
38.66
10.85
7.93

1.00
0.86
0.59
0.80

(referent)
(0.66–1.12)
(0.39–0.89)
(0.54–1.20)

7,102
14,161

33.40
66.60

211
508

29.35
70.65

1.00 (referent)
1.25 (1.04–1.49)

10,450
6,229
4,584

49.15
29.30
21.56

290
222
207

40.33
30.88
28.79

1.00 (referent)
1.21 (1.00–1.46)
1.23 (1.00–1.51)

14,275
6,988

67.14
32.86

525
194

73.02
26.98

1.00 (referent)
0.84 (0.70–1.00)

409
56.88
310
43.12
29.58 (6.63)

1.00 (referent)
1.20 (1.02–1.41)

0.58
0.61
0.001

0.97

0.002

0.015

<0.00001

0.04

0.015

0.06

0.046

0.03
13,750
64.67
6,495
30.55
28.85 (5.90)

0.004
(continued)
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Table 1

Continued
Frequent Memory Loss

Chronic condition(s) excl OA‡
No
Yes
No. conditions, mean (SD)
Per single comorbid condition increment
On lipid-lowering or antihypertensive medication
On other prescription medication§
Reproductive history (women,
N ¼ 10,236 without, 441 with memory loss)
Postmenopause
No
Yes
Don’t know
History of hormone replacement therapy
No
Yes

No (N ¼ 19,004)

Yes (N ¼ 719)

N

N

%

%

Adjusted OR* (95% CI) P†
<0.00001

13,227
62.21
8,036
37.79
0.55 (0.85)

323
44.92
396
55.08
0.94 (1.14)

1.00 (referent)
1.53 (1.28–1.80)

9,191
12,201

43.23
57.38

351
506

48.82
70.38

1.25 (1.16–1.35)
0.92 (0.76–1.11)
1.31 (1.07–1.59)

4,045
5,636
555

39.52
55.06
5.42

144
250
47

32.65
56.69
10.66

1.00 (referent)
0.97 (0.74–1.29)
1.96 (1.37–2.80)

6,328
3,908

61.82
38.18

231
210

52.38
47.62

1.00 (referent)
1.40 (1.12–1.74)

<0.00001
<0.00001
0.36
0.008

0.0002

0.003

BMI ¼ body mass index; CI ¼ confidence intervals; excl ¼ excluding; OA ¼ osteoarthritis; OR ¼ odds ratio.
*Adjusted for other factors in table.
†
All P values are two-sided.
‡
Including physician diagnosis of heart, kidney, liver, immune, connective tissue, and thyroid disease, hypertension, dyslipidemia,
diabetes, chronic obstructive pulmonary disease, or asthma.
§
Including nonsteroidal anti-inflammatory drugs.

Likewise, likelihood of perceived memory loss rose with
increasing frequency of OA-associated joint pain.
Relative to those without a reported diagnosis of OA,
adults indicating a diagnosis of OA and frequent joint
pain were five times more likely to report often
experiencing memory loss after controlling for age and
gender (OR ¼ 5.0, 95% CI ¼ 4.1–6.0, Ptrend < 0.00001)
(Table 2). After adjustment for additional demographics,
lifestyle characteristics, medical history, and other factors, OA symptom frequency remained strongly and
positively associated with reported memory loss (OR for
OA with frequent joint pain ¼ 3.3, 95% CI ¼ 2.6–4.0,
Ptrend < 0.00001). Restricting analyses to include only
those with self-reported OA yielded similar results (fully
adjusted OR for frequent vs no joint pain ¼ 3.6, 95%
CI ¼ 1.1–12.1, Ptrend ¼ 0.0002).
As detailed in Table 3, analyses broken down by frequent perceived short- and long-term memory loss
yielded similar findings. Relative to participants without
OA, those indicating a physician diagnosis of OA were
2.7 times as likely to report frequent short-term memory
loss and 2.6 times as likely to report frequent long-term
memory deficits after adjustment for demographics, lifestyle factors, BMI, menopausal status, and medical history (OR ¼ 2.7, 95% CI ¼ 2.2–3.3, and OR ¼ 2.6, 95%
CI ¼ 2.0–3.3) (Table 3). Likewise, compared with no OA,
the likelihood of both short- and long-term memory loss
increased significantly with rising frequency of reported

joint pain, with those indicating frequent joint pain more
than threefold as likely to indicate memory loss (ORs for
short and long-term memory loss, respectively ¼ 3.3,
95% CI ¼ 2.6–4.1, and 3.2, 95% CI ¼ 2.4–4.2,
Ptrend < 0.00001).
Additional adjustment for PFOA levels or for military service and associated chemical exposures did not appreciably alter risk estimates (OR for reported OA
diagnosis ¼ 2.7, 95% CI ¼ 2.2–3.3). Likewise, including
in the analyses participants with a reported diagnosis of
cancer, stroke, Parkinson’s disease, multiple sclerosis,
fibromyalgia, and other conditions linked to memory
loss and controlling for these conditions in the adjusted
models did not substantively change the association of
OA or OA symptom frequency to perceived memory
loss (OR for OA ¼ 2.7, 95% CI ¼ 2.3–3.2; OR for OA
with frequent joint pain ¼ 3.4, 95% CI ¼ 2.9–4.00,
Ptrend <0.00001).
Mood disturbance and sleep impairment scores were
strongly inter-related (adjusted r ¼ 0.53, P < 0.00001)
and were significantly and positively associated with reported OA diagnosis and associated frequency of joint
pain (P <0.00001). For example, relative to participants
scoring in the lowest mood and sleep impairment quartiles, those scoring in the highest quartiles were approximately three times as likely to report a physician
diagnosis of OA (ORs for highest vs lowest quartiles of
1345
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500
219
500
10
35
174
–

19,004
2,259
19,004
208
693
1,358
–

1.00
1.96
2.04
4.98

(referent)
(1.02–3.74)
(1.42–2.92)
(4.11–6.03)
–

1.00 (referent)
3.86 (3.23–4.62)

0.040
0.0001
<0.00001
<0.00001

<0.00001
1.00
1.80
1.74
3.93

(referent)
(0.83–1.03)
(1.21–2.50)
(3.23–4.78)
–

1.00 (referent)
3.14 (2.62–3.76)

OR (95% CI)

0.08
0.003
<0.00001
<0.00001

<0.00001

P

1.00
1.75
1.56
3.25

(referent)
(0.91–3.36)
(1.08–2.24)
(2.64–4.01)
–

1.00 (referent)
2.64 (2.18–3.20)

OR (95% CI)

P

0.10
0.02
<0.00001
<0.00001

<0.00001

Adjusted for Age, Sex, Race, SES,
Marital Status, Menopausal Status,
HRT, Lifestyle Factors†, BMI,
Comorbidity‡, and Medications§

BMI ¼ body mass index; CI ¼ confidence interval; HRT ¼ hormone replacement therapy; OA ¼ osteoarthritis; OR ¼ odds ratio; SES ¼ socioeconomic status (includes years of education, annual household income, and employment status/disability).
*Defined as a participant report of frequent short- or long-term memory loss.
†
Smoking (never, former, current); current alcohol consumption (yes/no); exercise (regular exercise program [yes/no]).
‡
Includes reported physician diagnosis of comorbid conditions (heart, kidney, liver, immune, connective tissue, and thyroid disease, hypertension, dyslipidemia, diabetes, chronic
obstructive pulmonary disease, or asthma).
§
Includes antihypertensive, lipid-lowering, and other prescription medications.

Osteoarthritis
No
Yes
OA joint pain severity
No OA
OA with joint pain never/rarely
OA with joint pain sometimes
OA with frequent joint pain
Test for trend

P

OR (95% CI)

N

Yes

Adjusted for Age and Sex

Reported History
of Memory Loss*

Adjusted for Age, Sex, Race,
SES, Marital Status, Lifestyle
Factors*

Table 2 Association of reported osteoarthritis (OA) and OA symptom severity to perceived memory loss (N ¼ 719 with and 21,263 without
reported history of memory loss) in Appalachian adults age 40 years or older (excluding those with history of stroke, Alzheimer’s disease;
fibromyalgia, rheumatoid arthritis, and other chronic pain syndromes, Parkinson’s Disease, multiple sclerosis, or cancer)
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281
116
281
1
20
95
–

19,223
217
708
1,437
–

399
10
28
147
–

19,105
208
700
1,385
–

19,223
2,362

399
584

19,105
2,293

Yes

(referent)
(1.25–4.59)
(1.33–2.96)
(4.15–6.30)
–

1.00
0.39
2.30
5.07

(referent)
(0.05–2.79)
(1.43–3.68)
(3.93–6.53)

1.00 (referent)
3.91 (3.08–4.96)

1.00
2.40
1.99
5.11

1.00 (referent)
3.97 (3.27–4.82)

OR (95% CI)

Adjusted for Age
and Sex

–
0.35
0.0005
<0.00001
<0.00001

–
<0.00001

–
0.008
0.001
<0.00001
<0.00001

–
<0.00001

P

(referent)
(1.14–4.25)
(1.13–2.52)
(3.23–4.94)
–

1.00
0.34
1.95
3.92

(referent)
(0.05–2.47)
(1.21–3.13)
(3.02–5.08)

1.00 (referent)
3.11 (2.44–3.96)

1.00
2.21
1.69
3.99

1.00 (referent)
3.20 (2.63–3.90)

OR (95% CI)

–
0.29
0.006
<0.00001
<0.00001

–
<0.00001

–
0.02
0.01
<0.00001
<0.00001

–
<0.00001

P

(referent)
(1.10–4.12)
(0.99–2.24
(2.62–4.12)
–

1.00
0.33
1.73
3.21

(referent)
(0.05–2.36)
(1.07–2.80)
(2.43–4.23)

1.00 (referent)
2.57 (1.99–3.33)

1.00
2.13
1.49
3.29

1.00 (referent)
2.68 (2.17–3.29)

OR (95% CI)

P

–
0.27
0.025
<0.00001
<0.00001

–
<0.00001

–
0.02
0.05
<0.00001
<0.00001

–
<0.00001

Adjusted for Age, gender, Race,
SES, Marital Status, Lifestyle
Factors*, Menopausal
Status, HRT, Comorbidity†,
and Medications‡

BMI ¼ body mass index; CI ¼ confidence interval; OA ¼ osteoarthritis; OR ¼ odds ratio; SES ¼ socioeconomic status (includes years of education, annual household income, and
employment status/disability).
*Smoking (never, former, current); current alcohol consumption (yes/no); exercise (regular exercise program [yes/no]).
†
Includes reported physician diagnosis of comorbid conditions (heart, kidney, liver, immune, connective tissue, and thyroid disease, hypertension, dyslipidemia, diabetes, chronic
obstructive pulmonary disease, or asthma).
‡
Includes antihypertensive, lipid-lowering, and other prescription medications.

Long-term memory loss
Osteoarthritis
No
Yes
OA joint pain severity
No OA
OA with joint pain never/rarely
OA with joint pain sometimes
OA with frequent joint pain
Test for trend

Short-term memory loss
Osteoarthritis
No
Yes
OA joint pain severity
No OA
OA with joint pain never/rarely
OA with joint pain sometimes
OA with frequent joint pain
Test for trend

N

Reported History
of Memory Loss

Adjusted for Age,
Sex, Race, SES,
Marital Status, Lifestyle
Factors*

Table 3 Association of reported physician diagnosed osteoarthritis (OA) and OA symptom severity to perceived short- and long-term memory
loss in 21,982 Appalachian adults age 40 years or older (excluding those with history of stroke, Alzheimer’s disease, fibromyalgia, rheumatoid
arthritis, and other chronic pain syndromes, Parkinson’s Disease, multiple sclerosis, or cancer)
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mood and sleep impairment, respectively ¼ 3.0, 95% CI
¼ 2.6–3.4, and 2.7, 95% CI ¼ 2.3–3.1). Mood and
sleep impairment were even more strongly related to reported history of memory loss (P <0.00001). For example, those with scores in the highest quartile of mood
and sleep disturbance were approximately 25- and
eightfold more likely to report a history of memory loss
(ORs for highest vs lowest quartiles of mood and sleep
impairment, respectively ¼ 24.5, 95% CI ¼ 14.9–40.4,
and 7.8, 95% CI ¼ 5.7–10.6). However, as illustrated in
Table 4, while inclusion of mood and sleep impairment
in the model attenuated the magnitude of the associations between perceived memory loss and OA and associated joint pain, the associations remained robust
(OR for reported OA adjusted for both sleep impairment
and mood swings ¼ 1.8, 95% CI ¼ 1.4–2.2,
P < 0.00001). These findings suggest that the relation of
OA to reported history of memory loss is only partially
mediated by mood and sleep.
Discussion
A growing body of literature suggests that chronic pain
can have significant negative effects on neurocognitive
function. Previous studies have documented memory
impairment in a number of chronic pain syndromes [9].
However, the potential link between memory loss and
OA, a leading cause of chronic pain, remains little studied. In this large cross-sectional study of older
Appalachian adults, self-reported history of memory loss
was strongly and positively associated with self-reported
physician diagnosis of OA and associated joint pain.
After adjustment for demographics, lifestyle factors,
BMI, medical history, medication use, and other factors,
participants indicating a physician diagnosis of OA were
2.6 times as likely to report experiencing frequent memory loss. The magnitude of this association increased
significantly with rising frequency of reported joint pain.
Mood and sleep impairment were strongly and positively
associated with both perceived memory loss and with
reported OA diagnosis and associated frequency of joint
pain; inclusion of these factors in the adjusted models
attenuated but did not eliminate these associations,
suggesting that mood and sleep disturbance may in
part mediate the observed relationships between OA
and perceived memory loss in this population.
The strong, independent association between OA and
reported memory loss observed in this study is consistent with the findings reported in most clinical studies of
other chronic pain syndromes, including migraine headaches, chronic low back pain, diabetic neuropathy,
rheumatoid arthritis, and fibromyalgia [9,24]. Likewise,
OA symptom frequency showed a strong, linear relationship to perceived memory loss in our study population,
in agreement with the significant correlations between
pain and cognitive performance documented in most,
although not all, previous studies of chronic pain syndromes [9,25]. These findings also parallel those from a
cross-sectional survey study of older British primary
care patients indicating a dose-response association
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between reported recent pain and cognitive complaints
that was not explained by co-occurring affective disorders [26]. The significant positive association of OA and
associated joint pain to perceived memory loss observed in this study was independent of demographic,
lifestyle, and health-related factors, including comorbidity and medication use.
Mood, Sleep, Pain, and Memory Loss
Pain is often accompanied by disruption of sleep and
mood; for example, depression has been documented
in 30% to 50% of chronic pain patients [27]. Current evidence from existing experimental, clinical, and epidemiologic studies suggests that the relationships between
musculoskeletal and other chronic pain, inadequate
sleep, and psychological distress are strongly reciprocal
[27–31]. Chronic pain can lead to significant disruption
of both sleep and mood [27,31–33]; conversely, accumulating research suggests that sleep deficits are
known to increase sensitivity to noxious stimuli and to
exacerbate both pain and affective symptoms
[28,30,31,34,35]. Similarly, depression, anxiety, and
other distressful states can lead to disordered sleep, as
well as increased pain [27,35–38]. In addition, a substantial body of evidence indicates that both affective
disturbance and sleep deficits can significantly and adversely influence memory and cognitive functioning [39–
48]. Disruption of mood and sleep may thus in part
mediate the documented negative effects of pain on
memory and cognitive performance. Consistent with
findings from these prior investigations, measures of
sleep and mood impairment were significantly interrelated in the current study and were strongly and positively associated with both OA and symptom frequency
and with history of perceived memory loss. That adjustment for these factors attenuated the association of OA
and associated joint pain to perceived memory loss in
our study population, albeit modestly, suggests that the
adverse changes in mood and sleep may in part explain
this relationship.
In agreement with the findings of previous studies
[49–54], reported history of memory loss in this study
was significantly and positively associated with smoking,
unemployment, and obesity, and was inversely associated with educational attainment, household income,
and engagement in regular physical activity. In addition,
both menopause and history of hormone replacement
therapy were positively associated with perceived memory loss among women in this study after adjustment for
other demographic, health, and lifestyle factors, consistent with the findings of most recent prospective investigations [55–57]. Consistent with the findings of some
[58–61], but not other, studies [61,62], reported memory
loss was also independently and positively associated
with female gender and retirement in our study population; recent studies suggest that these positive associations are stronger in those with lower cognitive reserve
[61,62], perhaps in part helping to explain the relationships observed in this study of Appalachian adults. In

500
219
500
10
35
174
–

19,004
2,259
19,004
208
693
1,385
–

1.00
1.80
1.42
2.18

(referent)
(0.92–3.52)
(0.98–2.06)
(1.76–2.70)
–

1.00 (referent)
1.96 (1.62–2.39)

0.09
0.06
<0.00001
<0.00001

<0.00001
1.00
1.87
1.61
2.34

(referent)
(0.96–3.65)
(1.11–2.35)
(1.87–2.93)
–

1.00 (referent)
2.13 (1.74–2.80)

OR (95% CI)

0.07
0.01
<0.00001
<0.00001

<0.00001

P

Adjusted for Demographics†,
Lifestyle Factors‡, BMI,
Reproductive/Medical History*,
and Mood Disturbance

1.00
1.86
1.53
1.83

(referent)
(0.93–3.70)
(1.05–2.22)
(1.45–2.29)
–

1.00 (referent)
1.76 (1.43– 2.16)

OR (95% CI)

0.08
0.03
<0.00001
<0.00001

<0.00001

P

Adjusted for Demographics†,
Lifestyle Factors‡, BMI,
Reproductive/Medical History§,
Sleep Impairment, and Mood Disturbance

BMI ¼ body mass index; CI ¼ confidence interval; OA ¼ osteoarthritis; OR ¼ odds ratio.
*Defined as a participant report of frequent short- or long-term memory loss.
†
Includes age, sex, race/ethnicity, years of education, annual household income, marital status, and employment status/disability.
‡
Smoking (never, former, current); current alcohol consumption (yes/no); exercise (regular exercise program [yes/no]).
§
Includes reported physician diagnosis of comorbid conditions (heart, kidney, liver, immune, connective tissue, and thyroid disease, hypertension, dyslipidemia, diabetes, chronic
obstructive pulmonary disease, or asthma) and use of antihypertensive, lipid-lowering, and other prescription medications; menopausal status and use of hormone replacement
therapy.

Osteoarthritis
No
Yes
OA joint pain severity
No OA
OA with joint pain never/rarely
OA with joint pain sometimes
OA with frequent joint pain
Test for trend

N

P

OR (95% CI)

Reported History
of Memory Loss*
Yes

Adjusted for Demographics†,
Lifestyle Factors‡, BMI,
Reproductive/Medical History*,
and Sleep Impairment

Table 4 Association of reported osteoarthritis (OA) and OA symptom severity to perceived memory loss (N ¼ 719 with and 21,263 without
history of memory loss) in Appalachian adults age 40 years or older: Influence of sleep and mood impairment
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contrast to the findings of most [63–67], but not all,
studies [66,68,69], perceived memory loss showed a
modest positive association with alcohol consumption in
the current study. Finally, the number of chronic conditions demonstrated a significant, positive linear association with reported memory loss in our study population.
While the relation of multimorbidity to cognitive decline
and cognitive impairment is complex, co-occurrence of
chronic conditions, especially those independently linked
to dementia, has been associated with subjective memory complaints [70] and with significantly greater risk of
incident mild cognitive impairment and dementia in several longitudinal studies [71–74], with some studies indicating a significant dose-response association between
number of conditions and risk increase [71,72].
Multimorbidity has also been linked to subjective memory complaints in nondemented adults [75,76].
Strengths and Limitations
This study has several strengths, including the
population-based design, high participation rates, and
large sample size. Additional strengths include our ability
to evaluate many potential confounders and modifiers,
to assess the potential mediating influence of sleep and
mood disturbance on the relation between perceived
memory loss and OA, and to examine potential doseresponse associations between OA pain frequency and
reported memory loss.
Our study has several limitations as well. Most important, the cross-sectional nature of our data precludes
determination of temporal or causal relationships. Our
study population was restricted to a largely nonHispanic white sample of Appalachian adults, potentially
limiting generalizability. We lacked information on certain
risk factors for memory loss, including history of head
trauma, as well as duration of memory loss. As the C8
Health Survey did not include cognitive testing, ascertainment of memory loss was reliant on self-report. A
potential concern relates to participant understanding of
short- vs long-term memory loss. While staff were on
hand to elaborate and/or answer questions on any of
the survey items, it is possible that some participants
did not discriminate accurately between short- and
long-term memory loss. An additional concern is the potential discrepancy between reported memory loss and
objective cognitive functioning. However, while subjective memory complaints do not always correlate with
deficits in objective cognitive performance [77], some
studies have shown significant relationships between
the two [77–79]. Moreover, although cognitive function
is in the normal range in those with subjective cognitive
decline [80], population-based studies have demonstrated significant decrements in cognitive performance
in adults with memory complaints relative to those without memory complaints [81,82]. Perhaps most important, prospective studies have shown subjective
memory complaints to be strongly predictive of accelerated cognitive decline and of incident mild cognitive impairment and Alzheimer’s Disease independent of
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demographics, lifestyle factors, depression, and other
risk factors for cognitive impairment [41,83–88].
Similarly, perceived memory loss has been linked to
neuropathological changes consistent with Alzheimer’s
disease [82,89–101], again suggesting that memory
complaints may represent a meaningful and potentially
sensitive marker of risk.
In addition, OA was determined based on participantreported physician diagnosis and was not confirmed by
chart review. While at least one previous clinical validation
study has shown self-report of general OA to be reliable
[22], consistent with the agreement between self-report
and medical record–verified data on another common
disorder, diabetes, in this study population [23], the accuracy of using self-reported diagnosis of OA for estimating
OA prevalence is unknown. The estimated crude OA
prevalence of 11.3% in this study was considerably lower
than prevalence estimates from other contemporaneous
population-based studies of older adults [102–106], suggesting that OA may have been underreported in this
study. However, such underascertainment would be expected to bias the observed associations toward the null,
and thus is unlikely to explain our findings. Likewise, the
prevalence of memory complaints reported in this study
was substantially lower than age-matched estimates documented in other population-based investigations
[26,107–111]. Thus, perceived memory loss may, like
OA, have been underreported, potentially attenuating the
relationships observed in this study.
Exclusion of eligible participants with missing data on
covariates may have introduced selection bias.
However, the percentage with missing data was small
(3.7%), and those with missing data did not differ in
most factors related to either OA or memory loss, rendering exclusion of these individuals unlikely to explain
the observed associations. Participants were informed
about the objectives of the study, which was conducted
in partial fulfillment of a settlement for a class action
lawsuit, potentially biasing reporting of health problems.
However, as noted above, both perceived memory loss
and OA were likely underascertained in this study, potentially attenuating observed associations and arguing
against possible overreporting by participants concerned
about the effects of PFOA. Hence, any bias introduced
by participant knowledge regarding the purpose of the
study is unlikely to explain our findings.
Although we adjusted for other prescribed medications,
we were unable to specifically assess the role of
NSAIDs or opioid medications. NSAIDS have been associated with reduced risk for incident cognitive impairment and dementia in several observational studies
[112,113] and with lower risk for cognitive decline in a
recent meta-analysis of 11 prospective cohort studies
[114]. While findings regarding the effects of therapeutic
opioid use on cognition have been inconsistent, many
clinical studies, including several rigorously conducted
randomized controlled trials, have found no association
between cognitive functioning and long-term opioid use
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for nonmalignant chronic pain [115–120], with some
studies showing pain relief from opioid therapy to be associated with improved cognitive performance [121].
Similarly, in a recent prospective cohort study of
community-dwelling US seniors, investigators found little
evidence for adverse effects of long-term opioid use on
cognition [122]. As most OA patients rely on NSAIDs
and other pain medications, failure to control for this
factor may have biased observed risk estimates, likely
toward the null. Thus, while the possibility cannot be
ruled out, use of NSAIDs or opioids is unlikely to explain
the strong positive associations observed between reported memory loss and OA in this study. Finally,
unmeasured confounding may also help explain our
findings, although our ability to control for a large number of both potential and known risk factors for memory
loss renders this possibility less probable.
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Conclusions
In this cross-sectional study of a large Appalachian population, history of perceived memory loss was strongly
and positively associated with self-reported physician diagnosis of OA and related joint pain, associations that
were only modestly attenuated by adjustment for sleep
and mood disturbance. Prospective studies using validated pain scales and objective measures of cognitive
performance are needed to investigate potential causal
associations and determine if symptomatic OA can contribute to cognitive decline and, ultimately, to incident
cognitive impairment.
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